# Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

> **NCT03960151** · PHASE2 · WITHDRAWN · sponsor: **Costantine Albany**

## Conditions studied

- Germ Cell Tumor

## Interventions

- **DRUG:** Rolapitant
- **DRUG:** Palonosetron
- **DRUG:** Olanzapine
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03960151
- **Lead sponsor:** Costantine Albany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-05
- **Primary completion:** 2021-05
- **Final completion:** 2022-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Compound was sold by funder and development ceased.
- **Last updated:** 2019-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03960151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03960151, "Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT03960151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*